idarubicin has been researched along with Acute Biphenotypic Leukemia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barba, G; Cicconi, L; Divona, M; Falini, B; Hasan, SK; Lo-Coco, F; Mecucci, C; Metzler, M; Ottone, T | 1 |
| Buyukasik, Y; Goker, H; Ozcebe, OI; Sayinalp, N; Serefhanoglu, S | 1 |
| Chignola, R; Dalla Pellegrina, C; Tomelleri, C | 1 |
| Broome, HE; Curtin, PT; Dell'Aquila, ML; Rashidi, HH; Thorson, JA; Wang, HY | 1 |
4 other study(ies) available for idarubicin and Acute Biphenotypic Leukemia
| Article | Year |
|---|---|
Clustering of genomic breakpoints at the MLL locus in therapy-related acute leukemia with t(4;11)(q21;q23).
Topics: Antibiotics, Antineoplastic; Base Sequence; Breast Neoplasms; Carcinoma, Ductal, Breast; Chromosome Breakpoints; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; Epirubicin; Female; Genetic Loci; Humans; Idarubicin; Leukemia, Biphenotypic, Acute; Leukemia, Promyelocytic, Acute; Middle Aged; Molecular Sequence Data; Multigene Family; Topoisomerase Inhibitors; Translocation, Genetic | 2014 |
Biphenotypic acute leukemia treated with acute myeloid leukemia regimens: a case series.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers; Case-Control Studies; Cytarabine; Female; Humans; Idarubicin; Immunophenotyping; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Retrospective Studies | 2009 |
Microplate spectrophotometry for high-throughput screening of cytotoxic molecules.
Topics: Animals; B-Lymphocytes; Cell Adhesion; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Colchicine; Culture Media; Cytotoxins; Epithelial Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Idarubicin; Kinetics; Leukemia, Biphenotypic, Acute; Paclitaxel; Sensitivity and Specificity; Spectrophotometry; T-Lymphocytes; Time Factors | 2010 |
t(4;22)(q12;q11.2) involving presumptive platelet-derived growth factor receptor A and break cluster region in a patient with mixed phenotype acute leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Breakage; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 4; Cytarabine; Female; Flow Cytometry; Humans; Idarubicin; Imatinib Mesylate; Immunophenotyping; In Situ Hybridization, Fluorescence; Karyotype; Karyotyping; Leukemia, Biphenotypic, Acute; Middle Aged; Phenotype; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic | 2011 |